Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aymara Sancho-Araiz

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pharmaceutics|August 10, 2021
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future PerspectivesAymara Sancho-Araiz, Victor Mangas-Sanjuan, Iñaki F Trocóniz
Clinical Pharmacology and Therapeutics|July 22, 2024
Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and PembrolizumabAymara Sancho-Araiz, Zinnia P Parra-Guillen, Iñaki F Troconiz, et al.
Journal of Clinical Pharmacology|May 2, 2025
A Systematic Evaluation of the Dosing Regimens for Approved Targeted Therapies and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma From a Project OPTIMUS PerspectiveZhiyuan Tan, Swantje Völler, Aymara Sancho-Araiz, et al.
Plos Computational Biology|October 4, 2023
Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironmentAymara Sancho-Araiz, Zinnia P Parra-Guillen, Jean Bragard, et al.
Pharmaceutical Research|December 21, 2021
Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population AnalysisCarolina Ameijeiras Rodríguez, Sara Carolina Henriques, Aymara Sancho-Araiz, et al.
Clinical Pharmacology and Therapeutics|May 12, 2023
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based ModelingZinnia P Parra-Guillen, Aymara Sancho-Araiz, Kapil Mayawala, et al.
Cancers|October 23, 2021
Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) TumorsAymara Sancho-Araiz, Sara Zalba, María J Garrido, et al.
Pharmaceutics|November 25, 2023
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune DiseasesNatalia Riva, Lucas Brstilo, Aymara Sancho-Araiz, et al.
Clinical Pharmacokinetics|May 21, 2026
Advancing Precision Dosing of 5-FU: Population PK Model Development, Limited Sampling Strategies, and Fit-for-Use ApplicationZhiyuan Tan, Aymara Sancho-Araiz, Swantje Völler, et al.
Critical Care (London, England)|May 14, 2026
Intrapulmonary penetration of ceftolozane/tazobactam and ceftazidime/avibactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trialAdela Benítez-Cano, Aymara Sancho-Araiz, Jesús Carazo, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pharmaceutics|August 10, 2021
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future PerspectivesAymara Sancho-Araiz, Victor Mangas-Sanjuan, Iñaki F Trocóniz
Clinical Pharmacology and Therapeutics|July 22, 2024
Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and PembrolizumabAymara Sancho-Araiz, Zinnia P Parra-Guillen, Iñaki F Troconiz, et al.
Journal of Clinical Pharmacology|May 2, 2025
A Systematic Evaluation of the Dosing Regimens for Approved Targeted Therapies and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma From a Project OPTIMUS PerspectiveZhiyuan Tan, Swantje Völler, Aymara Sancho-Araiz, et al.
Plos Computational Biology|October 4, 2023
Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironmentAymara Sancho-Araiz, Zinnia P Parra-Guillen, Jean Bragard, et al.
Pharmaceutical Research|December 21, 2021
Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population AnalysisCarolina Ameijeiras Rodríguez, Sara Carolina Henriques, Aymara Sancho-Araiz, et al.
Clinical Pharmacology and Therapeutics|May 12, 2023
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based ModelingZinnia P Parra-Guillen, Aymara Sancho-Araiz, Kapil Mayawala, et al.
Cancers|October 23, 2021
Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) TumorsAymara Sancho-Araiz, Sara Zalba, María J Garrido, et al.
Pharmaceutics|November 25, 2023
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune DiseasesNatalia Riva, Lucas Brstilo, Aymara Sancho-Araiz, et al.
Clinical Pharmacokinetics|May 21, 2026
Advancing Precision Dosing of 5-FU: Population PK Model Development, Limited Sampling Strategies, and Fit-for-Use ApplicationZhiyuan Tan, Aymara Sancho-Araiz, Swantje Völler, et al.
Critical Care (London, England)|May 14, 2026
Intrapulmonary penetration of ceftolozane/tazobactam and ceftazidime/avibactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trialAdela Benítez-Cano, Aymara Sancho-Araiz, Jesús Carazo, et al.
Pageof 1